How to buy Circassia Group stock

Circassia Group Plc is a business based in the US. Circassia Group shares (CSSPF) are listed on the OTCGREY and all prices are listed in US Dollars. Circassia Group employs 350 staff and has a market cap (total outstanding shares value) of USD$124.4 million.

How to buy shares in Circassia Group

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Circassia Group. Find the stock by name or ticker symbol: CSSPF. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Circassia Group reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Circassia Group, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Circassia Group. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Circassia Group share price

Use our graph to track the performance of CSSPF stocks over time.

Circassia Group shares at a glance

• Key figures

Information last updated 2021-01-23.

52-week range	USD$0.24 - USD$0.455
50-day moving average	USD$0.4311
200-day moving average	USD$0.3829
Wall St. target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Circassia Group shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Circassia Group stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Circassia Group Plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Circassia Group financials

Gross profit TTM	USD$46.2 million
Return on assets TTM	-12.43%
Return on equity TTM	-56.35%
Profit margin	-67.57%
Book value	N/A
Market capitalisation	USD$124.4 million

TTM: trailing 12 months

Circassia Group share dividends

We're not expecting Circassia Group to pay a dividend over the next 12 months.

Circassia Group share price volatility

Over the last 12 months, Circassia Group's shares have ranged in value from as little as $0.24 up to $0.455. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (OTCGREY average) beta is 1, while Circassia Group's is 1.8172. This would suggest that Circassia Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Circassia Group overview

Circassia Group Plc, a specialty pharmaceutical company, focuses on the development and commercialization of respiratory products. It operates through three segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; Tudorza for the treatment of COPD; and Duaklir, a fixed-dose combination of the long-acting muscarinic antagonist aclidinium bromide and long-acting beta agonist formoterol fumarate, which is administered twice-daily through the breath actuated Pressair inhaler for the maintenance treatment of COPD. It is also developing LungFit, a portable ventilator-compatible system that utilizes an electric voltage to produce precise quantities of nitric oxide from the nitrogen and oxygen in air. The company markets its products directly to specialists in the United States, the United Kingdom, China, Italy, and Germany, as well as through a network of partners internationally. Circassia Group Plc has a collaboration agreement with AstraZeneca to promote Tudorza and Duaklir for COPD treatment; and the United States and Chinese commercial rights to LungFit. The company was formerly known as Circassia Pharmaceuticals plc and changed its name to Circassia Group Plc in May 2020. Circassia Group Plc was founded in 2006 and is headquartered in Oxford, the United Kingdom.

Frequently asked questions

• What percentage of Circassia Group is owned by insiders or institutions?

  Currently 54.734% of Circassia Group shares are held by insiders and 35.114% by institutions.

• How many people work for Circassia Group?

  Latest data suggests 350 work at Circassia Group.

• When does the fiscal year end for Circassia Group?

  Circassia Group's fiscal year ends in December.

• Where is Circassia Group based?

  Circassia Group's address is: Northbrook House, Oxford, United Kingdom, OX4 4GA